Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 387

1.

Role of hypoxia-activated prodrugs in combination with radiation therapy: An in silico approach.

Meaney C, Powathil GG, Yaromina A, Dubois LJ, Lambin P, Kohandel M.

Math Biosci Eng. 2019 Jul 4;16(6):6257-6273. doi: 10.3934/mbe.2019312.

2.

Design, synthesis, in vitro inhibition and toxicological evaluation of human carbonic anhydrases I, II and IX inhibitors in 5-nitroimidazole series.

Aspatwar A, Parvathaneni NK, Barker H, Anduran E, Supuran CT, Dubois L, Lambin P, Parkkila S, Winum JY.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):109-117. doi: 10.1080/14756366.2019.1685510.

3.

Radiomics Analysis for Clinical Decision Support in Nuclear Medicine.

Ibrahim A, Vallières M, Woodruff H, Primakov S, Beheshti M, Keek S, Refaee T, Sanduleanu S, Walsh S, Morin O, Lambin P, Hustinx R, Mottaghy FM.

Semin Nucl Med. 2019 Sep;49(5):438-449. doi: 10.1053/j.semnuclmed.2019.06.005. Epub 2019 Jun 20. Review.

PMID:
31470936
4.

Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity.

Spiegelberg L, van Hoof SJ, Biemans R, Lieuwes NG, Marcus D, Niemans R, Theys J, Yaromina A, Lambin P, Verhaegen F, Dubois LJ.

Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)32975-5. doi: 10.1016/j.radonc.2019.06.034. [Epub ahead of print]

5.

Development and validation of a patient decision aid for prostate Cancer therapy: from paternalistic towards participative shared decision making.

Ankolekar A, Vanneste BGL, Bloemen-van Gurp E, van Roermund JG, van Limbergen EJ, van de Beek K, Marcelissen T, Zambon V, Oelke M, Dekker A, Roumen C, Lambin P, Berlanga A, Fijten R.

BMC Med Inform Decis Mak. 2019 Jul 11;19(1):130. doi: 10.1186/s12911-019-0862-4.

6.

Computed Tomography-based Radiomics for Risk Stratification in Prostate Cancer.

Osman SOS, Leijenaar RTH, Cole AJ, Lyons CA, Hounsell AR, Prise KM, O'Sullivan JM, Lambin P, McGarry CK, Jain S.

Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):448-456. doi: 10.1016/j.ijrobp.2019.06.2504. Epub 2019 Jun 26.

PMID:
31254658
7.

Performing clinical 18F-FDG-PET/MRI of the mediastinum optimising a dedicated, patient-friendly protocol.

Peerlings J, Paulis L, Mitea C, Bakers F, Berbée M, Wierts R, Vöö S, Wildberger J, Hoffmann A, Lambin P, Mottaghy F.

Nucl Med Commun. 2019 Aug;40(8):815-826. doi: 10.1097/MNM.0000000000001035.

PMID:
31169592
8.

Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG-PET/CT radiomics.

van Timmeren JE, Carvalho S, Leijenaar RTH, Troost EGC, van Elmpt W, de Ruysscher D, Muratet JP, Denis F, Schimek-Jasch T, Nestle U, Jochems A, Woodruff HC, Oberije C, Lambin P.

PLoS One. 2019 Jun 3;14(6):e0217536. doi: 10.1371/journal.pone.0217536. eCollection 2019.

9.

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology.

Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C; IBCD-Faculty.

Eur J Cancer. 2019 Jun;114:128-136. doi: 10.1016/j.ejca.2019.03.025. Epub 2019 May 3.

PMID:
31060925
10.

Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: Evaluation of the added prognostic value for overall survival and locoregional recurrence.

van Timmeren JE, van Elmpt W, Leijenaar RTH, Reymen B, Monshouwer R, Bussink J, Paelinck L, Bogaert E, De Wagter C, Elhaseen E, Lievens Y, Hansen O, Brink C, Lambin P.

Radiother Oncol. 2019 Jul;136:78-85. doi: 10.1016/j.radonc.2019.03.032. Epub 2019 Apr 11.

11.

Impact of SBRT fractionation in hypoxia dose painting - Accounting for heterogeneous and dynamic tumor oxygenation.

Kjellsson Lindblom E, Ureba A, Dasu A, Wersäll P, Even AJG, van Elmpt W, Lambin P, Toma-Dasu I.

Med Phys. 2019 May;46(5):2512-2521. doi: 10.1002/mp.13514. Epub 2019 Apr 14.

PMID:
30924937
12.

Stability of radiomics features in apparent diffusion coefficient maps from a multi-centre test-retest trial.

Peerlings J, Woodruff HC, Winfield JM, Ibrahim A, Van Beers BE, Heerschap A, Jackson A, Wildberger JE, Mottaghy FM, DeSouza NM, Lambin P.

Sci Rep. 2019 Mar 18;9(1):4800. doi: 10.1038/s41598-019-41344-5.

13.

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.

Spiegelberg L, Houben R, Niemans R, de Ruysscher D, Yaromina A, Theys J, Guise CP, Smaill JB, Patterson AV, Lambin P, Dubois LJ.

Clin Transl Radiat Oncol. 2019 Jan 18;15:62-69. doi: 10.1016/j.ctro.2019.01.005. eCollection 2019 Feb.

14.

Decision Support Systems in Oncology.

Walsh S, de Jong EEC, van Timmeren JE, Ibrahim A, Compter I, Peerlings J, Sanduleanu S, Refaee T, Keek S, Larue RTHM, van Wijk Y, Even AJG, Jochems A, Barakat MS, Leijenaar RTH, Lambin P.

JCO Clin Cancer Inform. 2019 Feb;3:1-9. doi: 10.1200/CCI.18.00001.

15.

Erratum: "Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers" [Med. Phys. 45 (7), 3449-3459 (2018)].

Deist TM, Dankers FJWM, Valdes G, Wijsman R, Hsu IC, Oberije C, Lustberg T, van Soest J, Hoebers F, Jochems A, El Naqa I, Wee L, Morin O, Raleigh DR, Bots W, Kaanders JH, Belderbos J, Kwint M, Solberg T, Monshouwer R, Bussink J, Dekker A, Lambin P.

Med Phys. 2019 Feb;46(2):1080-1087. doi: 10.1002/mp.13329. Epub 2019 Jan 7. No abstract available.

PMID:
30730570
16.

Improving decision making in larynx cancer by developing a decision aid: A mixed methods approach.

Petersen JF, Berlanga A, Stuiver MM, Hamming-Vrieze O, Hoebers F, Lambin P, van den Brekel MWM.

Laryngoscope. 2019 Dec;129(12):2733-2739. doi: 10.1002/lary.27800. Epub 2019 Jan 21.

PMID:
30663068
17.

Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients-An external validation.

Rizzo S, Raimondi S, de Jong EEC, van Elmpt W, De Piano F, Petrella F, Bagnardi V, Jochems A, Bellomi M, Dingemans AM, Lambin P.

Eur J Radiol. 2019 Jan;110:148-155. doi: 10.1016/j.ejrad.2018.11.032. Epub 2018 Nov 28.

PMID:
30599853
18.

Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric in silico ROCOCO trial.

Eekers DBP, Roelofs E, Cubillos-Mesías M, Niël C, Smeenk RJ, Hoeben A, Minken AWH, Granzier M, Janssens GO, Kaanders JHAM, Lambin P, Troost EGC.

Acta Oncol. 2019 Jan;58(1):57-65. doi: 10.1080/0284186X.2018.1529424. Epub 2018 Nov 26.

PMID:
30474448
19.

Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy.

Vanneste BGL, Buettner F, Pinkawa M, Lambin P, Hoffmann AL.

Clin Transl Radiat Oncol. 2018 Nov 3;14:17-24. doi: 10.1016/j.ctro.2018.10.006. eCollection 2019 Jan.

20.

Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients.

Klaassen R, Larue RTHM, Mearadji B, van der Woude SO, Stoker J, Lambin P, van Laarhoven HWM.

PLoS One. 2018 Nov 15;13(11):e0207362. doi: 10.1371/journal.pone.0207362. eCollection 2018.

Supplemental Content

Loading ...
Support Center